Erratum: Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels (Growth Factors (2012) 30 (124-139) DOI: 10.3109/08977194.2012.656759);Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels

Growth Factors

Volumn 30, Issue 2, 2012, Pages 124-139

  Manning, Janet R ^a   Carpenter, Gregory ^a   Porter, Darius R ^a   House, Stacey L ^a   Pietras, Daniel A ^a   Doetschman, Thomas ^a   Schultz, Jo El J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

extracellular signal regulated kinase (ERK); Growth factor; ischemia reperfusion; nitric oxide synthase; p38; PKC; transgenic mouse

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRITE; PROTEIN KINASE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; SARCOLEMMA; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 84858961437     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.745308     Document Type: Erratum

References (96)

1. Adak S, Santolini J, Tikunova S, Wang Q, Johnson JD, Stuehr DJ. 2001. Neuronal nitric-oxide synthase mutant (Ser-1412 → Asp) demonstrates surprising connections between heme reduction, NO complex formation, and catalysis. J Biol Chem 276: 1244-1252. (Pubitemid 32096552)
2. Adams JA, Wu D, Bassuk J, Arias J, Lozano H, Kurlansky P, Lamas GA. 2007. Nitric oxide synthase isoform inhibition before whole body ischemia reperfusion in pigs: Vital or protective? Resuscitation 74:516-525. (Pubitemid 47176768)
3. Bai YM, Murakami H, Iwasa M, Sumi S, Yamada Y, Ushikoshi H, Aoyama T, Nishigaki K, Takemura G, Uno B, Minatoguchi S. 2011. Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: Focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. Clin Exp Pharmacol Physiol 38:658-665.
4. Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL, Guo Y, Bolli R, Cardwell EM, Ping P. 2003. Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 92:873-880. (Pubitemid 36542528)
5. Barancik M, Htun P, Strohm C, Kilian S, Schaper W. 2000. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol 35:474-483. (Pubitemid 30127197)
6. Bell RM, Yellon DM. 2001. The contribution of endothelial nitric oxide synthase to early ischaemic preconditioning: The lowering of the preconditioning threshold. An investigation in eNOS knockout mice. Cardiovasc Res 52:274-280. (Pubitemid 33000404)
7. Bit RA, Davis PD, Elliott LH, Harris W, Hill CH, Keech E, Kumar H, Lawton G, Maw A, Nixon JS, Vesey DR, Wadsworth J, Wilkinson SE. 1993. Inhibitors of protein kinase C.3. Potent and highly selective bisindolylmaleimides by conformational restriction. J Med Chem 36:21-29. (Pubitemid 23040140)
8. Bolli R. 1990. Mechanism of myocardial "stunning". Circulation 82:723-738.
9. Bolli R, Marban E. 1999. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79:609-634. (Pubitemid 29210931)
10. Boussairi EH, Sassard J. 1994. Cardiovascular effects of basic fibroblast growth factor in rats. J Cardiovasc Pharmacol 23:99-102. (Pubitemid 24016848)
11. Budas GR, Churchill EN, Mochly-RosenD. 2007. Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol Res 55:523-536. (Pubitemid 46962304)
12. Buja LM, Entman ML. 1998. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 98:1355-1357. (Pubitemid 28462793)
13. Burkard N, Williams T, Czolbe M, Blomer N, Panther F, Link M, FraccarolloD, Widder JD, Hu K, Han H, Hofmann U, Frantz S, Nordbeck P, Bulla J, Schuh K, Ritter O. 2010. Conditional overexpression of neuronal nitric oxide synthase is cardioprotective in ischemia/reperfusion. Circulation 122:1588-1603.
14. Cohen MV, Yang XM, Downey JM. 2006. Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies. Cardiovasc Res 70:231-239. (Pubitemid 44316808)
15. Cohen MV, Yang XM, Downey JM. 1999. Smaller infarct after preconditioning does not predict extent of early functional improvement of reperfused heart. Am J Physiol 277:H1754-H1761.
16. Cohen MV, Yang XM, Liu Y, Solenkova NV, Downey JM. 2010. Cardioprotective PKG-independent NO signaling at reperfusion. Am J Physiol Heart Circ Physiol 299:H2028-H2036.
17. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364:229-233.
18. Cuevas P, Carceller F, Martinez-Coso V, Cuevas B, Fernandez- Ayerdi A, Reimers D, Asin-Cardiel E, Gimenez-Gallego G. 1999. Cardioprotection from ischemia by fibroblast growth factor: Role of inducible nitric oxide synthase. Eur J Med Res 4: 517-524.
19. Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Gimenez-Gallego G. 1991. Hypotensive activity of fibroblast growth factor. Science 254:1208-1210. (Pubitemid 21917455)
20. Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC. 2009. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296:H1236-H1243.
21. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B. 2005. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 112:3729-3737. (Pubitemid 43739513)
22. Detillieux KA, Sheikh F, Kardami E, Cattini PA. 2003. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 57:8-19. (Pubitemid 36009431)
23. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase. J Biol Chem 273:18623-18632. (Pubitemid 28334795)
24. Forstermann U. 2010. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 459:923-939.
25. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. 1994. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 23:1121-1131. (Pubitemid 24180877)
26. Forstermann U, Gath I, Schwarz P, Closs EI, Kleinert H. 1995. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol 50:1321-1332.
27. Gogelein H, Ruetten H, Albus U, Englert HC, Busch AE. 2001. Effects of the cardioselective KATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion. Naunyn Schmiedebergs Arch Pharmacol 364:33-41. (Pubitemid 32646338)
28. Gross GJ, Fryer RM. 1999. Sarcolemmal versus mitochondrial ATP-sensitive K + channels and myocardial preconditioning. Circ Res 84:973-979. (Pubitemid 29227676)
29. Grover GJ, Garlid KD. 2000. ATP-sensitive potassium channels: A review of their cardioprotective pharmacology. J Mol Cell Cardiol 32:677-695. (Pubitemid 30658936)
30. Guo Y, Li Q, Wu WJ, Tan W, Zhu X, Mu J, Bolli R. 2008. Endothelial nitric oxide synthase is not necessary for the early phase of ischemic preconditioning in the mouse. J Mol Cell Cardiol 44:496-501.
31. Hampton TG, Amende I, Fong J, Laubach VE, Li J, Metais C, Simons M. 2000. Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts. Am J Physiol Heart Circ Physiol 279:H260-H268. (Pubitemid 30616669)
32. Handy RL, Harb HL, Wallace P, Gaffen Z, Whitehead KJ, Moore PK. 1996. Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM) in vitro: Antinociceptive and cardiovascular effects. Br J Pharmacol 119:423-431. (Pubitemid 26326480)
33. Handy RL, Moore PK. 1997. Mechanism of the inhibition of neuronal nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM). Life Sci 60:PL389-PL394.
34. Hanley PJ, Daut J. 2005. K(ATP) channels and preconditioning: A re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 39:17-50. (Pubitemid 40836043)
35. Harada N, Miura T, Dairaku Y, Kametani R, Shibuya M, Wang R, Kawamura S, Matsuzaki M. 2004. NO donor-activated PKC-delta plays a pivotal role in ischemic myocardial protection through accelerated opening of mitochondrial K-ATP channels. J Cardiovasc Pharmacol 44:35-41. (Pubitemid 38857126)
36. Haylor J, Singh I, el Nahas AM. 1991. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int 39:333-335.
37. House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G, Schultz Jel J. 2003. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 108:3140-3148. (Pubitemid 38031805)
38. House SL, Branch K, Newman G, Doetschman T, Schultz Jel J. 2005. Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. Am J Physiol Heart Circ Physiol 289:H2167-H2175. (Pubitemid 41507370)
39. House SL, Melhorn SJ, Newman G, Doetschman T, Schultz JE. 2007. The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol 293:H354-H365. (Pubitemid 47105091)
40. Huang Z, Chen K, Huang PL, Finklestein SP, Moskowitz MA. 1997. bFGF ameliorates focal ischemic injury by blood flow-independent mechanisms in eNOS mutant mice. Am J Physiol 272:H1401-H1405.
41. Iwai-Kanai E, Hasegawa K, Fujita M, Araki M, Yanazume T, Adachi S, Sasayama S. 2002. Basic fibroblast growth factor protects cardiac myocytes from iNOS-mediated apoptosis. J Cell Physiol 190:54-62.
42. Jaburek M, Costa AD, Burton JR, Costa CL, Garlid KD. 2006. Mitochondrial PKC epsilon and mitochondrial ATP-sensitive K + channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res 99:878-883. (Pubitemid 44556387)
43. Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, Hao J, Cattini PA, Dixon IM, Kardami E. 2002. Acute protection of ischemic heart by FGF-2: Involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 282:H1071-H1080. (Pubitemid 34654947)
44. Jiang ZS, Srisakuldee W, Soulet F, Bouche G, Kardami E. 2004. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc Res 62: 154-166. (Pubitemid 38326821)
45. Jones SP, Bolli R. 2006. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40:16-23. (Pubitemid 43012113)
46. Kajita Y, Takayasu M, Yoshida J, Dietrich HH, Dacey RG, Jr. 2001. Vasodilatory effect of basic fibroblast growth factor in isolated rat cerebral arterioles: Mechanisms involving nitric oxide and membrane hyperpolarization. Neurol Med Chir (Tokyo) 41: 177-185, discussion 185-176.
47. Kawano T, Zoga V, Kimura M, Liang MY, Wu HE, Gemes G, McCallum JB, Kwok WM, Hogan QH, Sarantopoulos CD. 2009. Nitric oxide activates ATP-sensitive potassium channels in mammalian sensory neurons: Action by direct S-nitrosylation. Mol Pain 5:12-31.
48. Kharbanda RK. 2010. Cardiac conditioning: A review of evolving strategies to reduce ischaemia-reperfusion injury. Heart 96:1179-1186.
49. Kostyk SK, Kourembanas S, Wheeler EL, Medeiros D, McQuillan LP, D'Amore PA, Braunhut SJ. 1995. Basic fibroblast growth factor increases nitric oxide synthase production in bovine endothelial cells. Am J Physiol 269:H1583-H1589. (Pubitemid 3005960)
50. Kwak YG, Park SK, Cho KP, Chae SW. 1996. Reciprocal modulation of ATP-sensitive K + channel activity in rat ventricular myocytes by phosphorylation of tyrosine and serine/threonine residues. Life Sci 58:897-904. (Pubitemid 26075560)
51. Liao S. 2008. The role of fibroblast growth factor-2 isoforms in ischemia-reperfusion injury and cardioprotection. Cincinnati: University of Cincinnati.
52. Liao S, Porter D, Scott A, Newman G, Doetschman T, Schultz Jel J. 2007. The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: The role of JNK signaling. J Mol Cell Cardiol 42:106-120. (Pubitemid 44958632)
53. Liao S, Bodmer JR, Azhar M, Newman G, Coffin JD, Doetschman T, Schultz Jel J. 2010. The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury. J Mol Cell Cardiol 48:1245-1254.
54. Light PE, Bladen C, Winkfein RJ, Walsh MP, French RJ. 2000. Molecular basis of protein kinase C-induced activation of ATP-sensitive potassium channels. Proc Natl Acad Sci USA 97:9058-9063. (Pubitemid 30626673)
55. Lips DJ, Bueno OF,Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur J, Pages G, De Windt LJ, Doevendans PA, Molkentin JD. 2004. MEK1- ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109:1938-1941. (Pubitemid 38544482)
56. Marinovic J, Bosnjak ZJ, Stadnicka A. 2006. Distinct roles for sarcolemmal and mitochondrial adenosine triphosphate-sensitive potassium channels in isoflurane-induced protection against oxidative stress. Anesthesiology 105:98-104. (Pubitemid 44305197)
57. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D, Schachtele C. 1993. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268:9194-9197. (Pubitemid 23145960)
58. Massion PB, Balligand JL. 2003. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): Lessons from genetically modified mice. J Physiol 546: 63-75.
59. Mitchell MB, Winter CB, Banerjee A, Harken AH. 1993. The relationship between ischemia-reperfusion injury, myocardial stunning and cardiac preconditioning. Surg Gynecol Obstet 177: 97-114. (Pubitemid 23194043)
60. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MG. 1994. L-N6-(1-iminoethyl)lysine: A selective inhibitor of inducible nitric oxide synthase. J Med Chem 37: 3886-3888. (Pubitemid 24379677)
61. Murry CE, Jennings RB, Reimer KA. 1986. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136. (Pubitemid 17174962)
62. Namiki A, Akatsuka N. 1990. Vascular smooth muscle relaxation induced by epidermal growth factor is endothelium-dependent. Eur J Pharmacol 180:247-254. (Pubitemid 20170861)
63. O'Rourke B. 2004. Evidence for mitochondrial K + channels and their role in cardioprotection. Circ Res 94:420-432. (Pubitemid 38326277)
64. O'Rourke B. 2000. Myocardial K(ATP) channels in preconditioning. Circ Res 87:845-855.
65. Ohnuma Y, Miura T, Miki T, Tanno M, Kuno A, Tsuchida A, Shimamoto K. 2002. Opening of mitochondrial K(ATP) channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning. Am J Physiol Heart Circ Physiol 283:H440-H447. (Pubitemid 34705368)
66. Otani H. 2009. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal 11:1913-1928.
67. Padua RR, Sethi R, Dhalla NS, Kardami E. 1995. Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury. Mol Cell Biochem 143:129-135.
68. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. 2001. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. Faseb J 15:1487-1489.
69. Partovian C, Zhuang Z, Moodie K, Lin M, Ouchi N, Sessa WC, Walsh K, Simons M. 2005. PKCalpha activates eNOS and increases arterial blood flow in vivo. Circ Res 97:482-487. (Pubitemid 41298179)
70. Pasdois P, Beauvoit B, Costa AD, Vinassa B, Tariosse L, Bonoron- Adele S, Garlid KD, Dos Santos P. 2007. Sarcoplasmic ATPsensitive potassium channel blocker HMR1098 protects the ischemic heart: Implication of calcium, complex I, reactive oxygen species and mitochondrial ATP-sensitive potassium channel. J Mol Cell Cardiol 42:631-642. (Pubitemid 46349128)
71. Philipp S, Critz SD, Cui L, Solodushko V, Cohen MV, Downey JM. 2006. Localizing extracellular signal-regulated kinase (ERK) in pharmacological preconditioning's trigger pathway. Basic Res Cardiol 101:159-167. (Pubitemid 43250808)
72. Ping P, Takano H, Zhang J, Tang XL, Qiu Y, Li RC, Banerjee S, Dawn B, Balafonova Z, Bolli R. 1999. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: A signaling mechanism for both nitric oxide-induced and ischemia-induced preconditioning. Circ Res 84:587-604. (Pubitemid 29138595)
73. Pomblum VJ, Korbmacher B, Cleveland S, Sunderdiek U, Klocke RC, Schipke JD. 2010. Cardiac stunning in the clinic: The full picture. Interact Cardiovasc Thorac Surg 10:86-91.
74. Rajashree R, Koster JC, Markova KP, Nichols CG, Hofmann PA. 2002. Contractility and ischemic response of hearts from transgenic mice with altered sarcolemmal K(ATP) channels. Am J Physiol Heart Circ Physiol 283:H584-H590. (Pubitemid 34790852)
75. Rameau GA, Chiu LY, Ziff EB. 2004. Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor. J Biol Chem 279: 14307-14314. (Pubitemid 38468971)
76. Rameau GA, Tukey DS, Garcin-Hosfield ED, Titcombe RF, Misra C, Khatri L, Getzoff ED, Ziff EB. 2007. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci 27:3445-3455. (Pubitemid 46515122)
77. Saavedra WF, Paolocci N, Kass DA. 2002. Effects of cardioselective KATP channel antagonism on basal, stimulated, and ischaemic myocardial function in in vivo failing canine heart. Br J Pharmacol 135:657-662. (Pubitemid 34177643)
78. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH, Vandegaer K, Li D, Hare JM. 2005. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: Role of nitroso-redox equilibrium. Circulation 112:3415-3422. (Pubitemid 43739556)
79. Sato T, Sasaki N, Seharaseyon J, O'Rourke B, Marban E. 2000. Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection. Circulation 101:2418-2423. (Pubitemid 30329134)
80. Schultz JE, Qian YZ, Gross GJ, Kukreja RC. 1997. The ischemiaselective KATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart. J Mol Cell Cardiol 29: 1055-1060. (Pubitemid 27196532)
81. Schulz R, Kelm M, Heusch G. 2004. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 61:402-413. (Pubitemid 38210147)
82. Sears CE, Bryant SM, Ashley EA, Lygate CA, Rakovic S, Wallis HL, Neubauer S, TerrarDA, Casadei B. 2003. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 92:e52-e59.
83. Sharp BR, Jones SP, Rimmer DM, Lefer DJ. 2002. Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol 282:H2422-H2426. (Pubitemid 34663055)
84. Sheikh F, Sontag DP, Fandrich RR, Kardami E, Cattini PA. 2001. Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. Am J Physiol Heart Circ Physiol 280:H1039-H1050.
85. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA. 1996. Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells. Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha. J Biol Chem 271:1111-1117.
86. Strohm C, Barancik T, Bruhl ML, Kilian SA, Schaper W. 2000. Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J Cardiovasc Pharmacol 36:218-229. (Pubitemid 30659843)
87. Suzuki M, Sasaki N, Miki T, Sakamoto N, Ohmoto-Sekine Y, Tamagawa M, Seino S, Marban E, Nakaya H. 2002. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 109: 509-516. (Pubitemid 34171782)
88. Tiefenbacher CP, Chilian WM. 1997. Basic fibroblast growth factor and heparin influence coronary arteriolar tone by causing endothelium-dependent dilation. Cardiovasc Res 34:411-417. (Pubitemid 27241587)
89. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. 1994. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 45:598-604. (Pubitemid 24065099)
90. Tsuura Y, Ishida H, Hayashi S, Sakamoto K, Horie M, Seino Y. 1994. Nitric oxide opens ATP-sensitive K + channels through suppression of phosphofructokinase activity and inhibits glucose-induced insulin release in pancreatic beta cells. J Gen Physiol 104:1079-1098.
91. Uchiyama Y, Otani H, Okada T, Uchiyama T, Ninomiya H, Kido M, Imamura H, Nakao S, Shingu K. 2003. Integrated pharmacological preconditioning in combination with adenosine, a mitochondrial KATP channel opener and a nitric oxide donor. J Thorac Cardiovasc Surg 126:148-159. (Pubitemid 36909952)
92. Wang Y, Kudo M, Xu M, Ayub A, Ashraf M. 2001. Mitochondrial KATP channel as an end effector of cardioprotection during late preconditioning: Triggering role of nitric oxide. J Mol Cell Cardiol 33:2037-2046. (Pubitemid 33097281)
93. Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC. 1999. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 96:657-662. (Pubitemid 29061264)
94. Xu Z, Ji X, Boysen PG. 2004. Exogenous nitric oxide generates ROS and induces cardioprotection: Involvement of PKG, mitochondrial KATP channels, and ERK. Am J Physiol Heart Circ Physiol 286:H1433-H1440. (Pubitemid 38381152)
95. Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, El-Armouche A, Kranias EG, Casadei B. 2008. Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res 102:242-249. (Pubitemid 351651129)
96. Zhao T, Xi L, Chelliah J, Levasseur JE, Kukreja RC. 2000. Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A(1) receptors: Evidence from gene-knockout mice. Circulation 102:902-907.